Jagsonpal Pharma Recommends ₹4 Dividend; Q4 FY26 Standalone Results Declared
Jagsonpal Pharmaceuticals recommended a ₹4 per share dividend for FY26. The company declared its audited standalone financial results for the quarter and year ended March 31, 2026. A buy-back of up to 1,600,000 shares at ₹250 each, not exceeding ₹400 million, was also approved.
The dividend recommendation and the approval of a share buyback program are significant corporate actions that can impact shareholder value and company financials.
The recommendation of a dividend and the declaration of audited financial results are generally positive indicators for shareholders.
Jagsonpal Pharmaceuticals Limited announced its audited standalone financial results for the quarter and year ended March 31, 2026, following a Board Meeting held on April 27, 2026. The Board has recommended a dividend of ₹4 per equity share (200%) with a face value of ₹2 for the financial year ended March 31, 2026. This recommendation is subject to approval at the upcoming Annual General Meeting.
The company's financial statements were audited by Walker Chandiok & Co LLP, who issued an unmodified opinion. The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) and comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
During the fiscal year ended March 31, 2026, the company reported several significant events. These include the consolidation of labor legislations, an acquisition of Yash Pharma Laboratories' business, the mutual termination of an agreement for the gynaecology and dermatology divisions of Resilient Cosme-Ceuticals, the disposal of its Faridabad factory, and an impairment of certain property, plant, and equipment.
Furthermore, a proposal for the buy-back of up to 1,600,000 equity shares at ₹250 per share, for an aggregate consideration not exceeding ₹400 million, was approved by the Board on March 12, 2026, and subsequently by shareholders on April 27, 2026. The company also granted 1,152,500 stock options under its Employee Stock Option Plan 2022 and allotted 180,980 equity shares upon exercise of vested options.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.